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ABSTRACT 
Positron emission tomography (PET) is a non-invasive in vivo imaging technique used for 
translational biomedical research and clinical diagnosis. A fundamental pre-condition for PET 
is the radiolabelled tracer molecule used in the emission measurement, and there is a pressing 
need to accelerate the development of novel PET tracers to meet an increasing demand from 
the healthcare system, academia and drug industry. A cornerstone in this effort is access to 
methodologies for late-stage isotopic labelling of small molecules with the positron-emitting 
radionuclide carbon-11 (11C, half-life 20.4 min).  
The carbonyl group is one of the most abundant motifs in biologically important molecules and 
therefore a good target for isotopic labelling. The aim of this thesis was to develop 11C-
carbonylation reactions that made use of [11C]carbon dioxide ([11C]CO2), a synthon obtained 
directly from medical cyclotrons. The incorporation of this radiolabelled synthon, first into 
model compounds and later into biologically relevant molecules, was accomplished in 
automated radiochemistry systems and analysed using liquid chromatography.  
Papers I and II describe the development of two different methods for the synthesis of 11C-
labelled cyclic ureas. In Paper I, the noteworthy concept of CO2 fixation with strong, organic 
bases was applied. A set of [11C]benzimidazolones was thus radiolabelled with high 
radiochemical yields under mild conditions. In Paper II, the task was approached by using a 
click chemistry-inspired Staudinger/aza-Wittig cascade reaction. A wide selection of five and 
six-membered cyclic ureas was radiolabelled using this simple one-pot reaction. As a proof of 
concept, the β-adrenergic radioligand, (S)-[11C]CGP12177, was eventually produced using 
both methods. 
Paper III showcased a novel 12C/11C isotopic exchange reaction for labelling of phenylacetic 
acids. The method is based on heat-induced decarboxylation of the substrate molecule, 
followed by introduction of isotope-labelled [11C]CO2, without need for any additional 
reagents. Three small molecules, including two anti-inflammatory drugs, were labelled to 
prove suitability of the method for a low-concentration carbon-11 source. 
In Paper IV, the CO2 fixation concept was applied to the preparation of 
11C-labelled 
oxazolidinones and other cyclic urethanes, starting from corresponding anilines, benzylamines 
and dibromoalkanes. Five and six-membered cyclic urethanes, as well as both phenylic and 
benzylic compounds, were labelled with moderate to excellent radiochemical yields. 
In conclusion, a set of new methodologies was developed for the 11C-labelling of carbonyl 
groups. Each of the novel methodologies utilised [11C]CO2 obtained directly from a medical 
cyclotron without further chemical manipulation, and were successfully used in the preparation 
of cyclic ureas, benzoxazolone and benzothiazolone compounds, phenylacetic acids, N-
aryloxazolidinones, N-aryloxazinanones and N-benzyloxazinanones. Given the useful 
radiochemical yields and operational simplicity of these methods, there is a reason to be 
optimistic about their adoption in future PET tracer development.  
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1 INTRODUCTION 
1.1 Principles of PET 
1.1.1 PET methodology 
Positron emission tomography (PET) is a sensitive, non-invasive biomedical imaging 
technique that enables localisation of radioactive molecular tracers in living human subjects 
and experimental animals.1, 2 The tracers used in PET are labelled with unstable radioisotopes 
that emit a positron (e+), which travels a short distance in the surrounding tissue until it collides 
with an electron (e-). The energy of the positron is proportional to the travel distance of the 
radionuclide. The resulting annihilation event produces two 511 keV γ-rays which are emitted 
in nearly opposite directions. When a pair of γ-rays is coincidently detected in the scintillation 
crystals of the ring-shaped detector system around the subject, a signal is registered. A PET 
measurement consists of numbers of such coincidence events that are finally transformed into 
spatial information of the tracer and thus, an image. The resolution for modern pre-clinical PET 
is 0.8 mm3 and for clinical PET 1.5 mm4 full width at half maximum. Although the resolution 
of a PET measurement is inferior to that observed with magnetic resonance imaging (MRI), it 
provides an important opportunity for functional real-time imaging of metabolic or biochemical 
events that are very difficult to observe by other means.5 A dual PET/MR or PET/CT (computer 
tomography) measurement is normally conducted to combine the biochemical information 
from PET with anatomical images. Importantly, time-activity curves can be generated from the 
PET data, which allows for quantification of tracer distribution in tissue.  
1.1.2 Positron-emitting radionuclides 
The most commonly used radionuclides in PET are fluorine-18, carbon-11, oxygen-15 and 
nitrogen-13, which share a notably short half-life (2-110 minutes).6 Though the nuclides with 
short half-life are inconvenient from a radiochemistry perspective, they reduce the radiation 
burden for the subject and allow for multiple PET measurements in the same subject during a 
short time interval. PET radionuclides are commonly produced in medical cyclotrons, which 
are circular particle accelerators that typically have several reaction vessels (targets) in which 
the nuclear reactions take place. These cyclotrons are typically placed in an infrastructure 
together with a radiochemistry laboratory, which in turn is located at proximity of a nuclear 
medicine department or imaging research centre. However, not all imaging infrastructures have 
access to locally-produced radionuclides or PET tracers, and thus rely on external production 
facilities for PET tracer supply. This setup is almost exclusively adopted for 18F-labelled PET 
tracer synthesis due to its convenient 110 minutes half-life. Furthermore, not all radionuclides 
require a cyclotron for their production, but can be generated locally from an unstable “mother” 
radionuclide that is supplied in a radionuclide generator. Gallium-68 and copper-62 are 
examples of generator-produced metal nuclides that have gained popularity in the past years. 
Table 1 shows some PET nuclides and their physical properties.7 
  
 8 
Table 1. Summary of decay characteristics and common production routes of some commonly used radionuclides 
in PET. 
Radionuclide Half-life Energy of 
positrons (MeV) 
Type of reaction Portion of positron 
decay 
15O 2.0 min 1.72 14N(d,n)15O 100% 
13N 10.0 min 1.19 16O(p,α)13N 100% 
11C 20.4 min 0.96 14N(p,α)11C 100% 
18F 109.7 min 0.64 18O(p,n)18F 97% 
68Ga 68.1 min 1.90 68Ge → 68Ga + β- 90% 
64Cu 12.7 h 0.65 64Ni(p,n)64Cu 18% 
89Zr 78.4 h 0.90 89Y(p,n)89Zr 22% 
 
A PET tracer can be a radiolabelled drug molecule, biomolecule, receptor ligand or a simple 
gas. The biological half-lives vary significantly between these chemical species, it is thus 
important to select a radionuclide with a long enough half-life for its intended use. For example, 
small molecules such as pharmaceutical drugs, receptor ligands and peptides are ideally 
labelled using carbon-11, gallium-68 and fluorine-18. Larger biomolecules call for longer lived 
radionuclides, such as copper-64 and zirconium-89, whereas simple gasses like ammonia or 
water are labelled using nitrogen-13 and oxygen-15. To preserve the biological properties of a 
PET tracer, the radionuclide should ideally be introduced in a manner that does not alter its 
physicochemical or pharmacological properties. Nearly all biologically important molecules 
contain carbon and most of them contain nitrogen and/or oxygen atoms for such isotopic 
substitution. In contrast, fluorine, copper, gallium and zirconium atoms are scarcely observed 
in biomolecules and thus require structural modification to allow for their introduction. Of 
these, the introduction of fluorine-18 is the least perturbating whereas the labelling with metal 
radionuclides (68Ga, 64Cu and 89Zr) requires a relatively large chelating moiety in the target 
molecule, which makes these more suitable for peptides, nucleotides, nanoparticles and 
antibodies.8 
1.1.3 Applications of PET 
Today, PET is an established tool in clinical oncology, where it is used for diagnosis, to 
distinguish malignant tumours from benign, to track metastases and to follow the efficacy of 
treatments. The most widely used PET radiotracer is 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG), a fluorinated glucose analogue that is taken up into cells with high glucose 
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consumption, such as cancer cells.9 Following cellular uptake, [18F]FDG is phosphorylated but 
cannot be metabolised further, resulting in intracellular accumulation. In addition to [18F]FDG, 
PET imaging in oncology also takes advantage of a variety of other type of radiotracers, both 
routinely and as promising new methodologies. These include targeting cell proliferation with 
labelled thymidine analogues,10, 11 studying tumour blood flow with 15O-labelled water,12 
targeting tumour receptors with labelled antibodies13 and aptamers,14 and finally, following 
efficacy of gene therapy.15 
The risks associated with invasive brain research have led to the emergence of PET as an 
important tool in translational neuroscience research. In addition to the use of [18F]FDG to 
identify altered states of cerebral glucose metabolism (for example in Alzheimer’s disease16), 
there is an increasing arsenal of tracers available for imaging in neuroscience.17 Radiotracers 
targeting the brain must efficiently penetrate the blood-brain barrier (BBB), which sets specific 
requirements for the size and chemical structure of the potential tracer molecule. Successful 
tracers enter the brain via passive diffusion or active transport and are not substrates for efflux 
transporters located at the BBB that otherwise limit their brain exposure.18 Among the many 
radiotracers developed during the past decades, the most widely used tracers target the 
dopaminergic, serotonergic, cholinergic and glutamatergic neurotransmission systems. These 
tracers contribute to diagnosis and increased understanding of several neurological and 
psychiatric disorders such as depression, addiction, schizophrenia, Parkinson’s and 
Alzheimer’s disease. However, it is important to note that most receptors are still lacking a 
selective radiotracer and that there is still a great deal of work to be done in tracer 
development.19 PET is also routinely used in clinical cardiology, and examples of common 
tracers are [13N]ammonia, [11C]acetate, [11C]palmitate and [18F]FDG.2, 20 
PET radiotracers are often obtained at a high ratio between radioactivity and molar amount, or 
at a high “molar activity” (Am). A high Am is important in order to avoid saturation of target 
proteins in ligand binding studies, and it is typically recommended that less than 5-10% of 
target sites are occupied by the tracer during the PET measurement. However, it is also 
important to note that not all studies require high Am. Measurements of high capacity systems 
and drug biodistribution are examples of such studies.21 
A fundamental pre-requisite for conducting imaging studies in human subjects is that the tracer 
production complies with good manufacturing practice (GMP).6 To comply with GMP, a 
radiosynthesis should ideally be automated and carried out in an aseptic environment to exclude 
the introduction of microorganisms in the process. A number of quality requirements are 
typically imposed on GMP manufacturing procedures as well as on the end product. Among 
these, strict specifications are typically set to assure chemical and radiochemical purity and 
identity, molar activity, as well as sterility and apyrogenicity of the injection solution. However, 
due to short half-lives of the radionuclides, not all the quality control can be conducted before 
administration of the radiopharmaceutical. Strictly validated methods are thus used in 
radiotracer production. 
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1.2 PET radiochemistry 
1.2.1 Fluorine-18 
Fluorine-18 is the most widely used radionuclide in PET radiochemistry.22-24 Its convenient 
half-life permits both centralised production and transportation to radiochemistry facilities that 
lack an on-site cyclotron, as well as use in multistep radiosynthesis. In a similar manner as in 
organofluorine chemistry, the radiochemistry of fluorine-18 can be divided into electrophilic 
and nucleophilic methodologies. Despite the great scope associated with electrophilic 
fluorinations, this methodology is far less utilised in fluorine-18 radiochemistry due to practical 
issues associated with [18F]fluorine production, as well as the lower molar activity observed 
for the radiolabelled products. An exception to this is the relatively high molar activity obtained 
when utilising the electric discharge method, in which fluoromethane (produced from non-
carrier-added [18F]fluoride) is reacted with a low amount of fluorine gas25 which, however, 
requires careful control over reaction conditions. Most often a nucleophilic labelling approach 
is sought to simplify radiofluorinations from a practical perspective. Because of its high 
solvation energy, nucleophilic 18F-fluorinations rely on dried [18F]fluoride and the use of phase-
transfer catalysts (PTC) to increase its concentration in organic solvents. The dried 
[18F]fluoride-PTC complex can subsequently be used in both aliphatic23 and aromatic26 
radiofluorination reactions. Common leaving groups (LG) in nucleophilic aliphatic substitution 
include sulfonates (for example methyl and p-toluenesulfonate) and halides, whereas the 
corresponding LGs in aromatic fluorinations include nitro or trimethylammonium salts. 
However, not all compounds are optimally suited for nucleophilic aromatic fluorinations 
because they lack electron-withdrawing groups in ortho or para positions relative to the LG. 
Such compounds may be labelled using Cu-mediated reaction,27 Pd-mediated electrophilic 18F-
fluorination28 and aryl iodonium salts29. 
1.2.2 Carbon-11 
Carbon-11 is most often produced using the 14N(p,α)11C nuclear reaction by bombardment of 
nitrogen gas with protons. By adding a small amount of oxygen or hydrogen to the target gas, 
the labelling precursors [11C]carbon dioxide ([11C]CO2) and [
11C]methane ([11C]CH4) can be 
obtained, respectively (Scheme 1). Of these, [11C]CO2 is the more versatile precursor and, in 
addition to direct use, can be converted to secondary labelling precursors, like [11C]methyl 
iodide ([11C]CH3I)
30, 31 and [11C]carbon monoxide ([11C]CO)32, 33. These can in turn be 
converted into other useful radioactive synthons, such as [11C]phosgene ([11C]COCl2)
34-36, 
[11C]methyl triflate ([11C]CH3OTf)
37, 38, [11C]formaldehyde ([11C]CH2O)
39 and [11C]carbon 
disulfide ([11C]CS2)
40. Of these, [11C]CH3I and [
11C]CH3OTf are the most frequently used in 
11C-radiochemistry, whereas the other radiolabelled precursors are more seldom used owing to 
difficulties associated with their production. In general, high effectiveness and reactivity is 
often counterbalanced by time-consuming preparation, maintenance of the equipment and low 
reproducibility.22 [11C]CH4 does not permit direct labelling, but can be converted into 
[11C]hydrogen cyanide ([11C]HCN)41 or [11C]CH3I. An advantage with [
11C]CH3I derived from 
in-target produced [11C]CH4 is its higher molar activity that can be obtained due to the low 
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concentrations of methane in the atmosphere.42 However, a drawback is the lower yields 
typically observed for in-target produced [11C]CH4 compared to [
11C]CO2. 
 
 
Scheme 1. Primary and secondary 11C-precursors. Highlighted are [11C]CO2 (red), the most common primary 11C-
precursor, and [11C]CH3I and [11C]CH3OTf (grey), the most used 11C-labelling synthons.  
1.2.2.1 11C-Labelling using [11C]carbon dioxide  
Considering its 20-minute half-life, overall synthesis times with carbon-11 should be kept as 
short as possible. Being the most common 11C-labelled precursor obtained from the cyclotron, 
[11C]CO2 is a compelling option to be used directly, without chemical modifications. Many of 
the features sought in method development for carbon-11 radiochemistry are shared with those 
desired for novel methods for organic chemistry. Any new method would thus be optimised to 
achieve the highest possible yield of the product, under the mildest possible conditions and at 
the highest possible chemo and/or stereoselectivity. Challenges associated with [11C]CO2 
radiochemistry include low partial pressure of [11C]CO2 in inert gas, its relatively low reactivity 
and solubility. In addition, strict precautions need to be taken to avoid unnecessary dilution of 
the reaction mixture with atmospheric CO2, since this results in poor molar activity of the 
desired radiolabelled product. In synthetic organic chemistry, the incorporation of unlabelled 
CO2 often requires high partial pressure of the gas, high temperatures and catalysts. Since 
[11C]CO2 is obtained in minute quantities from the cyclotron, it is difficult to directly apply 
such methods to PET radiochemistry. Thus, only a handful of methods is available for direct 
or semi-direct incorporation of [11C]CO2. 
Carbamates and ureas are relatively common structural motifs in bioactive molecules and PET 
tracers. Although these structural motifs since long have been labelled using [11C]COCl2
43 the 
preparation of phosgene is cumbersome and hence not adopted in many PET centres. In an 
early [11C]urea synthesis, lithium hexamethyldisilazide (LiHMDS) was reacted with [11C]CO2 
and the subsequent lithium complex was hydrolysed using ammonium chloride.44 
Unfortunately, only [11C]urea and [11C]uracil were prepared using this method that has not 
found widespread use in the academic community. In another early example, [11C]CO2 was 
trapped at low temperature in a mixture of a substrate amine and triethylamine.45 The 
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intermediate carbamic acid was dehydrated with phosphoryl chloride (POCl3) to obtain 
11C-
labelled isocyanates and ureas. However, the approach suffered from the high reactivity of the 
intermediate [11C]isocyanate towards the precursor amine, resulting in low control over the 
products. There are also examples of ureas labelled using [11C]carbon monoxide.46, 47 
Considering the tedious preparation or narrow substrate scope for the previously presented N-
11C-carbonylation methods, a more straightforward and mild way of utilising [11C]CO2 was in 
demand. A big step forward was taken when the concept of carbon dioxide fixation for labelling 
was presented.48, 49 Strong, organic bases, so-called fixating agents, enable efficient trapping of 
[11C]CO2 into the reaction mixture and activate it towards heteroatom-[
11C]carbon bond 
formation (Scheme 2). Although Coenen and co-workers already used triethylamine for 
[11C]CO2 fixation,
45 these so-called superbases, such as DBU (1,8-diazabicyclo[5.4.0]undec-
7-ene) and BEMP (2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphos-
phorine), have proven to be excellent fixating agents even at room temperature and moderate 
gas flow rates. The nature of the base-CO2 intermediate remains still unclear. A zwitterionic 
intermediate has generally been proposed, but at least in case of DBU, only formation of 
bicarbonate salt has been confirmed.50, 51 
In their publications, both Hooker and Wilson used the fixation base chemistry for preparation 
of 11C-labelled carbamates (A in Scheme 2).48, 49 It was shown that the putative intermediate, 
the carbamate salt formed between the base, amine and carbon dioxide could be alkylated 
directly with reactive alkyl electrophiles. The method, which was operationally simple, 
consisted of bubbling [11C]CO2 through a solution of the fixation base (DBU or BEMP), an 
amine and a halide, tosylate or sulfate. It was later discovered that more structurally complex 
[11C]carbamates could be prepared via an active [11C]isocyanate intermediate, which could be 
formed by dehydrating the carbamate salt with POCl3 (B in Scheme 2).
52 In the same report, 
Wilson and co-workers also demonstrated that the [11C]isocyanate intermediate could be 
reacted with amines to provide the corresponding [11C]ureas, although transformation was not 
very efficient for aromatic ureas. Other labelled heterocyclic compounds, such as 
[11C]oxazolidinones, were also readily available when amino and hydroxy functionalities were 
pre-installed into the substrate, as demonstrated for [11C]SL25.1188.53 This radiotracer for 
monoamine oxidase-B (MAO-B), that was originally labelled using [11C]COCl2,
54 has also 
been applied to research in human subjects.55 Furthermore, the same methodology has been 
applied to the production of the fatty acid amide hydrolase PET tracer [11C]CURB for 
application in human PET studies.56 
Mitsunobu conditions have also been applied as an efficient alternative to POCl3 treatment in 
the synthesis of [11C]isocyanates (C in Scheme 2).57 Importantly, these conditions were mild 
(often carried out at room temperature) and allowed for excellent RCYs for both symmetrical 
and unsymmetrical [11C]ureas even with aniline substrates.57, 58 It was later demonstrated that 
[11C]amides could be prepared when the Mitsunobu reaction was followed by alkylation with 
Grignard reagent.59 
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Scheme 2. Possible pathways (A-C) for [11C]carbamate and [11C]urea formation using [11C]CO2 fixation 
chemistry. 
There are several other methods reported in the literature for 11C-heteroatom bond formation 
that do not require superbases for CO2 fixation (Scheme 3). Van Tilburg and colleagues 
reported an alternative for 11C-labelling of ureas by using phosphinimine precursors obtained 
from the corresponding primary amines (Scheme 3a).60 Though high reaction selectivity was 
observed for a set of linear [11C]ureas, the methodology was hampered by relatively low 
radiochemical yield. Direct 11C-methylation of amines with [11C]CO2 has also been reported, 
instead of using traditional [11C]CH3I or [
11C]CH3OTf (Scheme 3b).
61 Although this Zn-
mediated method had several drawbacks (high temperature, long reaction time and moderate 
substrate scope), it was reminded that direct utilisation of [11C]CO2 would often simplify set-
ups and automation. The authors were able to apply the method to the radiosynthesis of 
[11C]PIB, a β-amyloid radiotracer, with moderate RCY but low molar activity. Finally, 
[11C]carbonates were synthesized starting from an alcohol and alkyl chloride (Scheme 3c).62 
DBU was not suitable for this method but the authors presented two possible alternative 
approaches. In the first one, using cesium carbonate (Cs2CO3) as a base, high RCYs but low 
molar activities were obtained. When using sodium hydride (NaH) instead, molar activities 
were high but RCYs only moderate. As a disadvantage, scope for the method was not 
presented. 
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Scheme 3. Miscellaneous 11C-heteroatom bond formation reactions. a) [11C]Ureas from phosphinimines. b) Direct 
11C-methylation of amines. c) [11C]Carbonates from [11C]CO2. 
Strongly basic organometallic reagents have since long been used for 11C-carboxylation 
reactions in 11C-C bond formation (Scheme 4a and b). Simple [11C]carboxylic acids (Route A 
in Scheme 4a), such as [11C]acetic and [11C]palmitic acid have thus been obtained by reacting 
the corresponding Grignard reagents with [11C]CO2.
63-65 Further functionalisation of such 11C-
carboxylated species into esters and amides has been facilitated by reaction of the intermediate 
[11C]carboxymagnesium halides with thionyl chloride, phthaloyl dichloride or oxalyl chloride 
to form the corresponding [11C]acyl halides (B in Scheme 4a).66, 67 [Carbonyl-11C]WAY-
100635, prepared via this route, is arguably the most widely used PET tracer for imaging 
serotonin 1A receptors (5HT1A) in human subjects.
68-71 Additionally, [11C]amide can be 
reduced to [11C]amine, as demonstrated in the synthesis of (+)-[11C]PHNO, a dopamine D2/D3 
radioligand.72 Lasne and co-workers developed a direct reaction between the 
[11C]carboxymagnesium halide and amine to obtain a set of amides (C in Scheme 4a).73 It is 
noteworthy that [11C]amines were accessible using this route when sodium borohydride 
(NaBH4) was present in the reaction mixture (D in Scheme 4a).
74 Radiochemical yields (RCY) 
for the 11C-amidation were considerably enhanced by applying microwave heating, and as a 
proof of concept, the 5HT1A agonist S14506 was 
11C-labelled with 10-18% RCY.75, 76 
Organolithium compounds have also found use in 11C-carboxylation chemistry. The labelling 
synthon [11C]acetone has been successfully prepared using methyllithium (Scheme 4b).77, 78 
However, due to the high reactivity and sensitivity of organometallic reagents, several 
problems arise. If reagents are not stored under an inert atmosphere, they are prone to react 
with atmospheric CO2, leading to reduced molar activities of the 
11C-labelled products. The 
syntheses often require complicated set-ups, and functional group tolerance in the target 
molecule is typically poor. A recently developed copper-mediated protocol for labelling of 
[11C]carboxylic acids and derivatives starting from the corresponding boronic acid esters 
  15 
addressed some of these shortcomings (Scheme 4c).79 Functional group tolerance was higher 
with this method, but only aryl, vinyl and alkynylboronates were compatible as substrates. An 
oxytocin receptor ligand79 as well as the retinoid X receptor (RXR) agonist bexarotene80 were 
labelled using the method. Another way to overcome the problems arising from the use of 
organometallic reagents was presented by Borganzone and colleagues in their work that 
harnessed fluorine-activated silylated aryl precursors for carboxylation (Scheme 4d).81 
Trapping efficiency for [11C]CO2 was greatly enhanced in the presence of BEMP or DBU. 
 
Scheme 4. Synthesis of [11C]carboxylic acid derivatives using a) Grignard, b) organolithium, c) boronate ester and 
d) silane chemistry. 
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AIMS OF THE THESIS 
The overall aim of the thesis was to develop new 11C-labelling methods using [11C]carbon 
dioxide directly from the cyclotron, and thus facilitate development and discovery of novel 
radiotracers for PET. The specific aims were the following: 
• To develop methods for 11C-labelling of cyclic ureas and benzimidazolones, as well as 
to label (S)-[11C]CGP12177, a radioligand used for imaging of β-adrenergic receptors. 
• To apply dynamic isotope exchange to 11C-labelling of carboxylic acids. 
• To develop a method for 11C-labelling of N-phenyl-2-oxazolidinones and other cyclic 
urethanes. 
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2 MATERIALS AND METHODS 
A brief summary of materials and methods is presented below. For detailed synthesis 
procedures and radiochemistry methodology, the reader is referred to the full papers and 
manuscript. 
2.1 Preparation and handling of [11C]carbon dioxide 
All gases were purchased from AGA Gas AB (Sundbyberg, Sweden). Carbon-11 was produced 
with a GEMS PETtrace cyclotron (GE Uppsala, Sweden) using 16.4 MeV protons via the 
14N(p,α)11C nuclear reaction. [11C]CO2 was prepared in a 78 mL aluminium target containing 
nitrogen gas of scientific grade purity (99.9999%) and a small amount of oxygen (0.5 or 1%). 
[11C]CO2 was transferred either directly to a hot cell or via intermediate purification on 
molecular sieves inside a chemical process cabinet (GE, Uppsala, Sweden). 
Inside the hot cell, [11C]CO2 was delivered to a [
11C]CO-synthesizer prototype from GEMS 
PET Systems AB (GE Healthcare, Uppsala, Sweden), where it was trapped either on a 
molecular sieve column (0.6 g packed in a ¼” stainless steel tube, 4 Å, mesh 80/100, GRACE) 
at room temperature (RT) or a stainless steel loop immersed in liquid nitrogen. The 
accumulated [11C]CO2 was released into a controlled stream (10 mL/min, Mass flow controller, 
Bronckhorst) of helium (He 6.0) upon heating. The purified [11C]CO2 was further concentrated 
on a silica gel (10 mg, 60 Å, 60-100 mesh) trap immersed in liquid nitrogen.  After heating, 
[11C]CO2 was transferred via a phosphorus pentoxide (P2O5) column into a reaction vessel 
using a controlled stream of helium.  
The reaction vessel pre-charged with the reaction mixture, was equipped with an ascarite 
(sodium hydroxide-coated silica, 8-20 or 20-30 mesh) trap to measure untrapped [11C]CO2. 
Following completed entrapment, the needles were removed, and the vessel was kept at the 
desired temperature for the specified reaction time. By comparing decay-corrected activities 
(A) in the vial and the ascarite trap, trapping efficiency 1 (TE1) could be determined using the 
following Equation 1. TE1 gives an estimation about the ability of the reaction mixture to retain 
[11C]CO2, and is subject to improvement by using CO2 trapping agents or optimising the 
conditions, such as temperature or gas flow rate. Nevertheless, part of the radioactive gas is 
naturally in the headspace of the reaction vial, thus creating uncertainty to the TE1 values. 
Equation 1: TE1 = (
A1, vial
A1, vial + A1, ascarite
) × 100% 
When the reaction was complete and quenched, the vial was flushed with N2 to release the 
[11C]CO2 that still remained unreacted, into a second ascarite trap to estimate trapping 
efficiency 2 (TE2) according to Equation 2. TE2 can be seen as a measurement of the efficacy 
of the reaction in terms of [11C]CO2 usage. 
Equation 2: TE2 = (
A2, vial
A2, vial + A2, ascarite
) × 100% 
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2.2 Product identification and yield determination 
Analytical high-performance liquid chromatography (HPLC) system equipped with both 
radioactivity and UV detectors, was used for product identification. By co-injecting a non-
radioactive reference compound, the radioactive peak could be associated with the 
corresponding UV peak co-eluting with the desired product. Radiochemical purity (RCP) of 
the desired product in the crude mixture was evaluated by comparing the radioactivity peak 
areas in the chromatogram. Total radiochemical yield (RCY) was then calculated using the 
Equation 3: 
Equation 3: RCY = TE1 × TE2 × RCP 
2.3 Molar activity 
Molar activity (Am, GBq/µmol) was calculated by dividing the activity (GBq) of the product 
sample with the chemical amount of the tracer molecule (µmol). Analytical HPLC was used 
for determination of the concentration of carrier in the product solution. 
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3 RESULTS AND DISCUSSION 
3.1 11C-labelling of cyclic ureas (Papers I and II) 
Five and six-membered cyclic ureas, including benzimidazolones, are commonly found in 
biologically and pharmaceutically relevant molecules. These structural motifs are traditionally 
labelled using [11C]COCl2.
43 To circumvent the difficulties associated with preparation and use 
of [11C]COCl2, we directed our efforts to developing methods for direct 
11C-carbonylation 
using cyclotron-produced [11C]CO2. This first subproject thus introduces two complementary 
ways to label such motifs. 
3.1.1 11C-labelling of benzimidazolones using CO2 fixation chemistry 
The aim of the first study presented in Paper I was to develop an efficient method for 
preparation of 11C-labelled benzimidazolones, including the PET tracer (S)-[11C]CGP12177 
((S)-4-(3-(tert-butylamino)-2-hydroxypropoxy)-2H-benzimidazol-2[11C]-one) (Figure 1) that 
has been used for β-adrenergic receptor imaging.82-84 The method was inspired by the fruitful 
concept of CO2 fixation that allows for utilising the minute amounts of 
11C-labelled CO2 
obtained from the cyclotron target.  
 
Figure 1. Structure of (S)-[11C]CGP12177. The [11C]benzimidazolone moiety is highlighted. 
For optimisation, 11C-carbonylation of o-phenylenediamine (1a) with [11C]CO2 was selected 
as a model reaction (Table 2). DBU and BEMP were selected as fixating agents, as it has been 
shown that [11C]CO2 can be efficiently trapped in a reaction mixture by using these 
superbases.48, 49, 85 The radiolabelling procedure was started by trapping [11C]CO2 at room 
temperature in the presence of the fixating agent and o-phenylenediamine dissolved in a solvent 
of choice. Subsequently, a dehydrating agent was added and the reaction vessel was kept at a 
designated temperature for 4 min.  
Following the conditions outlined in previous methodologies,45, 52 POCl3 was first tested as a 
dehydrating agent for the intermediate [11C]isocyanate formation. Although trapping efficiency 
in the presence of BEMP was high, [11C]benzimidazolone (2a) was afforded with low RCP 
(11%, Entry 1). Alternatively, aromatic 11C-labelled ureas have previously been prepared via a 
Mitsunobu reaction approach.57, 58, 86 More specifically, a complex of a tertiary phosphine and 
dialkyl azodicarboxylate is used to activate carbamic acid formed by amine and [11C]CO2. 
Gratifyingly, by adding a mixture of di-tert-butyl azodicarboxylate (DBAD) and n-
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tributylphosphine (PBu3) after [
11C]CO2 trapping, the target molecule was afforded in high 
RCP (98%, Entry 2). DBU used in Entry 2 was less efficient as a trapping agent, and later 
comparison between DBU and BEMP verified this observation. Solvent screening revealed 
that MeCN, DMF and DMSO afforded both high TEs and RCPs (Entries 4-6), while THF was 
less suitable for CO2 fixation (Entry 3). Next, a comparison of three different phosphines (PPh3, 
PMePh2 and PBu3) was conducted (Entries 7-9). Although RCYs were similar for all the 
phosphines, PBu3 was selected due to the combination of high reactivity in the solution and 
stability on the bench. It was also noticed that the reaction proceeded well at room temperature. 
Finally, in the absence of a fixating base, only moderate TE was achieved (Entry 10). 
Table 2. Optimisation of reaction conditions for the synthesis of [11C]benzimidazolone. 
 
Entrya Solvent Additive T [°C] TE [%]b RCP [%]c RCY [%]d 
1e MeCN POCl3 RT 93 11 10 
2f MeCN PBu3 50 38 98 37 
3 THF PPh3 RT 48 80 38 
4 DMSO PBu3 50 80 96 77 
5 DMF PBu3 50 92 85 78 
6 MeCN PBu3 50 96 99 95 
7 MeCN PPh3 RT 85 95 81 
8 MeCN PMePh2 RT 99 95 94 
9g MeCN PBu3 RT 92 ± 4 99 ± 1 91 ± 1 
10h MeCN PBu3 RT 51 99 50 
[a] Reaction conditions: [11C]CO2 was bubbled into a solution of o-phenyleneamine (22.9 μmol, 2.5 mg) and 
BEMP (1.4 equiv) dissolved in the designated solvent (0.5 mL) at room temperature. The solution was reacted for 
1 minute, after which a solution of DBAD (2.0 equiv) and additive (2.0 equiv) in 0.1 mL of the same solvent was 
added. The reaction mixture was kept at the designated temperature for additional 4 min. [b] Trapping efficiency, 
TE = TE1 x TE2. [c] Radiochemical purity, decay-corrected, estimated by radio-HPLC. [d] Radiochemical yield, 
RCY = TE x RCP. [e] o-Phenyleneamine (27.5 μmol), solvent 0.6 mL, BEMP 0.2 equiv, no DBAD, additive 0.08 
equiv. [f] DBU (0.044 equiv) instead of BEMP. According to Haji Dheere et al.57 [g] The mean value ± SD, n=3. 
[h] No fixating agent eg. BEMP. 
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With optimised conditions in hand, we studied the suitability of the reaction for labelling of 
benzimidazolones with different functional groups (Figure 2). High RCYs, varying from 83% 
to 99%, were achieved from o-phenylenediamines bearing both electron-withdrawing and 
donating groups (2b-f). Also, other heterocycles, namely oxazolidinone 2g and thiazolone 2h, 
were labelled with 83% and 95% RCY, respectively. N-Methylated substrate 1i was readily 
transformed to the desired product, but N,N´-dimethylated 1j required heating to afford 18% 
RCY. The lower reactivity could be resulting from steric hindrance caused by the methyl 
groups, or from the requirement for the reaction to proceed via a different mechanism. 
Isocyanate formation after dehydration of the carbamate salt can occur only for primary amines 
(Scheme 5, Route A). Hence, in the case of N,N´-dimethyl-o-phenylenediamine, formation of 
isocyanate is ruled out and a direct attack of the amino group to the activated 
carbamoyloxyphoshonium would occur instead (Route B). 
 
Figure 2. Substrate scope for the 11C-labelling of benzimidazolones. The isotope-labelled carbon-11 is marked 
with an asterisk. Percentages represent RCYs. [a] Solvent MeCN/DMF 1:1. [b] Reaction at 60 °C. 
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Scheme 5. Two possible reaction routes for the formation of benzimidazolone under Mitsunobu conditions. 
Route A (purple): Isocyanate formation followed by ring closure. Route B (blue): Direct attack to the 
carbamoyloxyphosphonium group. The isotope-labelled carbon is marked with an asterisk. 
As mentioned, the method was developed in attempt to facilitate 11C-labelling of (S)-
CGP12177. In the first labelling attempt with an unprotected hydroxy-diamine precursor, only 
8% RCP was achieved. Nevertheless, after protecting the reactive hydroxyl group, 
radiolabelling was achieved with >99% conversion (Scheme 6). In a preparative run, (S)-
[11C]CGP12177 was afforded with 23% RCY after deprotection and semi-preparative HPLC 
purification. Radiochemical purity was >99% and molar activity 14 GBq/µmol. 
 
Scheme 6. Labelling and subsequent deprotection of (S)-[11C]CGP12177. 
Labelling of [11C]CGP12177 with [11C]COCl2 has previously afforded molar activities of 4.8 
GBq/µmol for the racemic mixture83 and 252-518 GBq/µmol for the S-enantiomer87 in 25 
minutes from end of bombardment (EOB). [11C]COCl2 has been prepared from [
11C]CO and 
later, from [11C]CH4.
36, 88 Despite the advantage obtained in terms of higher molar activity, 
production of [11C]COCl2 is troublesome. All preparation methods are time-consuming 
multistep syntheses, and a characteristic problem for production of [11C]COCl2 is low 
reproducibility. So far, there is no widespread production system for [11C]COCl2 and only few 
laboratories produce it routinely. In this sense, production of [11C]CGP12177 using [11C]CO2 
directly from the cyclotron using the new method presented herein, is clearly advantageous. As 
a downside, due to reactivity of the hydroxyl group, an additional protection-deprotection 
procedure is required. 
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3.1.2 11C-Labelling of cyclic ureas using click chemistry 
Another method for 11C-labelling of cyclic ureas directly from [11C]CO2 was developed in close 
collaboration with colleagues at the French Alternative Energies and Atomic Energy 
Commission (CEA) in Saclay, Paris and is presented in Paper II. This novel method relied on 
the Staudinger/aza-Wittig reaction, a “click”-type reaction that uses organic azides as substrates 
in the formation of isocyanate intermediates. An azide reacts with a phosphine (PR3) to form 
an iminophosphorane which then reacts with CO2 (Scheme 7). The resulting isocyanate reacts 
readily with the nearby amino group to close the cyclic structure. 
 
Scheme 7. Staudinger/aza-Wittig cascade reaction to form cyclic urea from an aza-amino precursor. 
The method was first developed for carbon-14 labelling at the CEA. Initial reaction 
optimisation was conducted with the cheaper alternative, [13C]CO2. o-Azidoaniline was used 
as a model substrate to select adequate phosphine, solvent, temperature and time. Using highly 
reactive PPhMe2 in DMF, the target molecule was afforded with 95% yield in only 5 minutes 
at 25 °C for both carbon-13 and carbon-14. Encouraged by the short reaction time, the 
conditions were tested for carbon-11 labelling. Gratifyingly, 79% RCP was obtained when 
trapping of [11C]CO2 at -50 °C was followed by the reaction at 25 °C. 
The optimised conditions were next applied to labelling of several cyclic ureas, of which seven 
(Figure 3), including (S)-[11C]CGP12177 were labelled at the Karolinska Institutet PET centre 
and the rest at the CEA. Excellent RCPs (85-99%) were obtained for the compounds 4b-g, 
including five and six-membered ureas. A preparative run for (S)-[11C]CGP12177 afforded the 
target molecule 4h in 34% isolated yield after HPLC purification and in a molar activity of 
32.5 GBq/µmol. Though somewhat better than that obtained with the Mitsunobu method 
presented earlier (14 GBq/µmol), the obtained Am is still not high enough for receptor 
occupancy studies. Yet, both of these molar activities are useful for tracking distribution of the 
tracer in the body. Compared to the laborious synthesis of [11C]CGP12177 using [11C]COCl2, 
for this Staudinger/aza-Wittig method, the same important advances apply: Use of [11C]CO2 
directly from cyclotron in a rapid and mild one-pot reaction affords the labelled molecule in 
one step. As a disadvantage, an azide is needed as starting material, which could possess special 
safety restrictions, and requires some synthetic efforts. The method has excellent 
chemoselectivity, as relatively complex molecules, including a peptide and (S)-
[11C]CGP12177 were labelled without any pre-protection.  
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Figure 3. Scope for 11C-labelling of cyclic ureas using Staudinger/aza-Wittig approach. Presented are the 
compounds labelled at the KI PET centre. The isotope-labelled carbon is marked with an asterisk. The nitrogen 
originating from the azido group is marked with a grey circle. The percentages represent RCPs estimated from 
radio-HPLC. [a] Isolated RCY. 
To conclude, both of these methods presented in the Papers I and II, introduce a mild and fast 
way to label cyclic ureas with [11C]CO2. Suitability of these methods for labelling of PET 
tracers was highlighted by successful labelling of (S)-[11C]CGP12177.
 
3.2 12C/11C Isotopic exchange in phenylacetic acids (Paper III) 
Today, isotopic exchange is a well-established method in labelling of molecules, especially 
with deuterium and tritium.89-91 Unfortunately, labelling with carbon isotopes has traditionally 
required multistep syntheses. The journey towards carbon isotope exchange started by 
discovery of copper-assisted decarboxylation of aryl carboxylic acids.92 Inspired by this 
pioneering work, in 2019 Destro and co-workers at the CEA used this as the starting point for 
12C/13C and 12C/14C isotope exchange.93 The same year, Kingston and co-workers published a 
nickel-mediated decarboxylative isotopic exchange for alkyl carboxylic acids.94 Moon et al. 
discovered that phenyl carboxylic acids undergo heat-induced decarboxylation,95 and inspired 
by this, our collaborators at the CEA developed a transition metal-free procedure for carbon 
isotope exchange (Scheme 8). In collaboration with the CEA, we applied this method to 11C-
labelling, as there are no current examples of 12C/11C isotope exchange. 
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Scheme 8. Dynamic isotopic exchange for aryl carboxylic acids. Asterisk refers to 11C/13C/14C. 
In this method presented by the collaborators at the CEA, a cesium salt of phenylacetic acid is 
simply heated in presence of [13C/14C]CO2. It was hypothesized that after decarboxylation, the 
benzylic anion would react directly with labelled CO2 or it would generate a dienolate species. 
This intermediate would attack to CO2 and form a malonate that would finally lose the 
excessive carboxyl group. Nevertheless, in a recent article by Kong and co-workers,96 the 
authors 13C-labelled α-substituted carboxylates that cannot form an enolate, thus arguing that 
the route including the dienolate intermediate is not necessary for the reaction to proceed. 
The reaction conditions for the isotopic exchange were optimised by the collaborators at the 
CEA. For the model compound, cesium salt of 4-methoxyphenylacetate, in presence of 3 equiv. 
of [13C]CO2, a reaction in anhydrous DMSO at 150 °C afforded the highest isotopic enrichment 
(IE) (43%). Nevertheless, during the substrate scope studies, it was noticed that many substrates 
required a specific temperature and time for the optimal IE, ranging between 80 and 190 °C 
and from 5 minutes to 6 hours. 2-(4-Nitrophenyl)acetic acid, flurbiprofen and tolmetin 
precursors were amongst the swiftly reacting compounds, and they were selected for further 
11C-labelling tests at the KI PET centre. 
For 11C-labelling of 2-(4-nitrophenyl)acetic acid (6a), some further optimisation was 
conducted. The optimal results were achieved when [11C]CO2 was trapped at room temperature 
in the presence of 50 µmol of the cesium salt precursor 5a in 0.5 mL DMSO, followed by 
heating at 80 °C for 5 min, affording 61% TE1, 82% TE2, >99% RCP and 50% total RCP 
(Figure 4). A preparative run for 5a was conducted using the optimised conditions. After HPLC 
purification, the 11C-labelled target molecule was achieved with >99% RCP and 11% overall 
RCY. Molar activity was 0.16 GBq/µmol.   
After trials and errors, 11C-labelling of flurbiprofen (6b in Figure 4) and tolmetin (6c) were 
conducted in 10 minutes at 150 °C, affording RCYs of 7% and 3%, respectively. 
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Figure 4. Isotopic exchange with [11C]CO2. Yields refer to RCY = TE1 x TE2 x RCP. [a] Preparative run, 
isolated RCY. 
In this pioneering study for 12C/11C exchange, three substrates were radiolabelled with carbon-
11 although higher number of suitable substrates can be expected to be found by further 
screening. High reaction temperatures could be an issue affecting to general suitability of the 
method. The same concern arises with the loss of stereochemistry, which is a built-in feature 
of the method. Lastly, RCYs and molar activities for this CO2 exchange were low, though 
potentially useful. It is important to emphasise the simplicity of this method; Labelling was 
completed in one step using [11C]CO2 directly, and without need for special precursors or 
reagents. 
3.3 11C-Labelling of oxazolidinones and other cyclic urethanes (Paper IV) 
Encouraged by CO2 fixation and 
11C-labelling of benzimidazolones in the 1st project, our next 
goal was to label other heterocycles, namely cyclic urethanes. Owing to their superior features 
in vivo, such as higher stability, compared to peptides, urethanes have become particularly 
important within medicinal chemistry.97 To obtain 11C-labelled oxazolidinones, one possible 
approach is to construct a β-amino alcohol precursor that undergoes intramolecular cyclisation 
in presence of either [11C]COCl2 or [
11C]CO2. Two PET tracers for monoamine oxidase 
receptor imaging have been prepared using either of these methodologies: [11C]befloxatone for 
MAO-A98  and [
11C]SL25.1188 for MAO-B53, 54. Additionally, selenium-mediated synthesis of 
five and six-membered cyclic urethanes with [11C]CO has been presented.47 
In synthetic chemistry with unlabelled CO2, there are various ways to construct oxazolidinones 
but few of them are suitable for late-stage carbon-11 chemistry due to requirements in starting 
material functionalisation or reaction conditions, as most often high CO2 pressure is applied. 
The Repo group at the University of Helsinki developed a simple method to construct N-aryl 
and N-benzyl oxazolidinones using moderate CO2 pressure and simple precursors.
99 The 
oxazolidinone ring is formed between an aniline precursor, CO2 and 1,2-dibromoethane, and 
bigger rings are achieved using dibromoalkanes with longer alkyl chain. In collaboration with 
Repo and co-workers, our aim was to adapt the method to 11C-labelling.  
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The method development was initiated using aniline dissolved in MeCN as precursor, 1,2-
dibromoethane as alkylating reagent, [11C]CO2 as labelling agent, and with 2-tert-
butyltetramethylguanidine (2-tBuTMG) and cesium carbonate (Cs2CO3) as additives. The 
reaction was conducted in one pot by trapping [11C]CO2 into the reaction mixture at room 
temperature and keeping the vial at 60 °C for 15 minutes. Delightfully, the first reaction 
furnished the target compound with 64% TE1, 19% TE2, 95% RCP and total RCY of 11%. 
After initial screening for solvent, additives, substrate concentrations, time and temperature, 
we found out that 0.34 M of aniline, 1,2-dibromoethane and 2-tBuTMG afforded high TE1 
(82%) and RCY (66%) in 5 minutes at 90 °C (Table 2, Entry 1). Chemically, high [11C]CO2 
trapping was obtained in concert with the fixating agent and aniline but physical features arising 
from the reaction set up and vial dimensions also affected the TE1. 
Other fixating agents at the same basicity area were tested and of these, BEMP performed as 
well as 2-tBuTMG, while tetramethylguanidine (TMG) and DBU were less successful. 
Surprisingly, triazabicyclodecene (TBD) was unable to yield any product despite the similar 
pKa value. More reactive electrophiles ethylene di(p-toluenesulfonate) and 2-bromoethyl p-
toluenesulfonate were not compatible. Reducing the amount of 1,2-dibromoethane further to 
0.03 M affected TE2 negatively (Entry 2). A reaction conducted at 50 C afforded also lower 
TE2 (Entry 3). Prolongation of the reaction time up to 10 minutes enhanced RCY (Entry 4) but 
the improvement was cancelled by decay of carbon-11. Finally, the necessity of a fixating base 
was highlighted as the absence of 2-tBuTMG affected negatively to TE1 and prevented 
formation of the target compound (Entry 5). 
Table 2. Optimisation of reaction conditions for 11C-labelling of oxazolidinones. 
 
Entry Deviation from standard 
conditions 
TE1 [%] TE2 [%] RCP [%] RCY [%]
a 
1 noneb 82 ± 6 91 ± 2 88 ± 1 66 ± 7 
2 0.01 mmol 1,2-dibromoethanec 84 77 85 55 
3 50 °Cc 76 64 85 41 
4 10 minc 87 94 91 74 
5 no fixating basec 40 11 0 0 
[a] RCY = TE1 x TE2 x RCP. [b] Conditions: 7a (0.10 mmol, 0.34 M), 1,2-dibromoethane (0.10 mmol, 0.34 M), 
2-tBuTMG (0.10 mmol, 0.34 M) and [11C]CO2 in DMF (250 µL) at 90 °C for 5 min. n=3. [c] n=1. 
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The optimised reaction conditions (Entry 1 in Table 2) were applied to labelling of different 
substrates. First, oxazolidinones with different functional groups were studied (Figure 5). 
Methoxy-substituted oxazolidinone was labelled with high RCY (8b, 79%), as well as 3-(3-
fluoro-4-morpholinophenyl)oxazolidinone (8e, 78%), a motif found in antibiotic Linezolid. 
Electron-withdrawing groups lowered the yields for 8c and 8d. Ring expansion to 
oxazinanones was made simply by using 1,3-dibromopropane as an electrophile, allowing for 
labelling of 8f-h. Another possible application arised from labelling of benzylic oxazinanones 
by using benzylamine as a precursor, as shown with 8i-k. By lowering the amount of fixating 
base to 0.1 equiv. the higher reactivity of benzylamine was controlled. 
 
Figure 5. RCYs for the labelled [11C]phenyleneoxazolidinones 8a-e, [11C]phenyleneoxazinanones 8f-h and 
[11C]benzyloxazinanone derivatives 8i-k using the optimised conditions, n = 2. The carbon-11 isotope is marked 
with an asterisk. 
Finally, a preparative run for 8e was conducted. After HPLC purification, the radiolabelled 
product was isolated in 63% RCY, while RCP was over 99%. The determined molar activity 
was 4.7 GBq/µmol, which would be suitable for drug distribution studies. The radiotracers 
[11C]SL25.1188 and [11C]befloxatone are the only examples of 11C-labelled oxazolidinones, 
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and any general method for labelling this structural motif starting from corresponding anilines 
and dihaloalkanes has not been published so far. The method presented herein approaches from 
a direction that utilises simple, convertible building blocks, allowing for easy construction of 
different cyclic urethanes.  
In general, several reasons can be recognised for the molar activities that do not reach high 
values during these projects. In addition to site-specific restrictions in target efficacy, dilution 
of radiolabelled [11C]CO2 by atmospheric CO2 is a feature that is difficult to eliminate. Use of 
CO2 trapping agents (Papers I and IV), such as BEMP and 2-tBuTMG, is a potential reason 
for lower Am. Additionally, the reaction mechanism of isotope exchange reaction (Paper III) 
lowers Am inevitably. 
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4 CONCLUDING REMARKS 
In this thesis, novel methodologies were developed that allowed access to 11C-labelled cyclic 
ureas, benzoxazolones and benzothiazolones, phenylacetic acids, N-aryloxazolidinones, N-aryl 
and N-benzyl oxazinanones directly from cyclotron-produced [11C]CO2 (Figure 6). The 
methods shared some important features, namely operational simplicity (one-pot procedures), 
short reaction times, and generally high radiochemical yield and selectivity of the target 
compounds. This work has contributed to availability of 11C-labelling methods for small 
molecules, which has an impact on PET tracer development. The studies presented herein have 
a possibility to add knowledge about labelling methods with other carbon isotopes, as well as 
to contribute to CO2 chemistry in general. 
 
Figure 6. Summary of the 11C-carbonylations and carboxylations presented in this thesis. 
The key conclusions from Papers I-IV are the following: 
• The work in Paper I presented a new simple method to label benzimidazolones using 
[11C]CO2 fixation and Mitsunobu reaction. In Paper II, a complementary way to label 
cyclic ureas using a Staudinger/aza-Wittig reaction was presented. The yields of both 
reactions were high, and the utility was showcased in each case by labelling of the PET 
tracer (S)-[11C]CGP12177. 
• In Paper III, a novel dynamic isotopic exchange reaction was presented. To the best 
of our knowledge, this is the first time that isotope exchange was used in carbon-11 
chemistry. The utility of the methodology was demonstrated in the labelling of three 
phenylacetic acid compounds, including two anti-inflammatory drugs in useful 
radiochemical yields for imaging studies. 
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• In Paper IV, a novel method for 11C-labelling of aryl oxazolidinones and other cyclic 
urethanes was presented. In this general method, aniline and dihaloalkane building 
blocks were used to construct 11C-labelled phenylic and benzyl oxazolidinones as well 
as oxazinanones. The reaction provided the target products in moderate to excellent 
radiochemical yields. 
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5 FUTURE CONSIDERATIONS 
PET imaging is a well-established tool in diagnosis, research and development. Nevertheless, 
the number of radiotracers available is still limited compared to possible imaging targets. On 
one hand, development of radiochemistry methods for late-stage labelling is important in order 
to achieve goals in radioligand discovery. Despite the recent advancements, there is still plenty 
of space and demand for new 11C-labelling methods that are general and preferably compatible 
for clinical use.  
Ease of automation is an important feature of a good labelling method, and this would be a 
plausible next step for some of the methods presented in this thesis. The exciting isotope 
exchange reaction that was debuting with carbon-11, will require more attention in terms of 
generality, substrate scope and molar activity. Molar activity has been a challenge for all of the 
presented methods, and solutions could be assessed when possible. 
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